Status: Recruiting
EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers
This study is to evaluate the safety and antitumor activity of EMB-01 in advanced/metastatic gastrointestinal cancers, including gastric cancer, hepatocellular cancer, cholangiocarcinoma and colorectal cancer.
Participants needed: 152
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Shanghai EpimAb Biotherapeutics Co., Ltd.Updated: Aug 26, 2024Locations: 14
Eligibility criteria
cMET amplification in tumor sample; OR [+13]
Patients who are unwilling to sign the molecular pre-screening ICF. [+7]